- Home
- AUST vs CING Comparison
AUST vs CING Comparison
Compare AUST & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- CING
- Stock Information
- Founded
- AUST 2020
- CING 2012
- Country
- AUST Canada
- CING United States
- Employees
- AUST N/A
- CING N/A
- Industry
- AUST
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- AUST
- CING Health Care
- Exchange
- AUST Nasdaq
- CING Nasdaq
- Market Cap
- AUST 15.5M
- CING 15.3M
- IPO Year
- AUST 2022
- CING 2021
- Fundamental
- Price
- AUST $1.25
- CING $5.03
- Analyst Decision
- AUST
- CING Strong Buy
- Analyst Count
- AUST 0
- CING 2
- Target Price
- AUST N/A
- CING $12.00
- AVG Volume (30 Days)
- AUST 92.5K
- CING 222.7K
- Earning Date
- AUST 03-03-2025
- CING 11-07-2024
- Dividend Yield
- AUST N/A
- CING N/A
- EPS Growth
- AUST N/A
- CING N/A
- EPS
- AUST N/A
- CING N/A
- Revenue
- AUST N/A
- CING N/A
- Revenue This Year
- AUST N/A
- CING N/A
- Revenue Next Year
- AUST N/A
- CING N/A
- P/E Ratio
- AUST N/A
- CING N/A
- Revenue Growth
- AUST N/A
- CING N/A
- 52 Week Low
- AUST $0.62
- CING $1.80
- 52 Week High
- AUST $3.19
- CING $58.32
- Technical
- Relative Strength Index (RSI)
- AUST 46.23
- CING 58.30
- Support Level
- AUST $1.05
- CING $4.50
- Resistance Level
- AUST $1.27
- CING $5.16
- Average True Range (ATR)
- AUST 0.10
- CING 0.43
- MACD
- AUST 0.03
- CING 0.00
- Stochastic Oscillator
- AUST 64.82
- CING 57.66
About AUST Austin Gold Corp.
Austin Gold Corp is a gold exploration and development company focused on gold targets and making district-scale gold discoveries in Nevada. Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Fourmile Basin in Nye County.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.